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Abstract
Background: Leishmaniases are vector-borne diseases caused by the protozoa of the Leishmania genus. The clinical
spectrum of these diseases extends from benign dermal lesions to visceral forms. In the Mediterranean region,
zoonotic visceral leishmaniasis (ZVL) is caused by L. infantum. If untreated within two years, the disease usually
leads to death. In Morocco, ZVL is endemic in the north, with a hundred cases notified each year, mostly in
children aged below five years. Here, we report on two clinical observations in infants presenting unusual concomitant
VL and cutaneous leishmaniasis (CL) in Morocco.
Case presentation: In this case study, we report on two infants aged nine and 12 months old. They both have a
history of febrile splenomegaly, anemia, and pallor of mucous membranes. Visceral leishmaniasis was confirmed
by parasitological diagnosis (positive bone marrow smear and screening of anti-L. infantum antibodies). However,
the clinical examination also showed cutaneous lesions that suggested the presence of CL. This was reinforced by
the patients having a history of living or traveling to endemic foci. Thus, direct examination, culture, and PCR-RFLP (ITS1-
Hae 3) were carried out on the patients’ dermal exudates. In one of the infants, CL was associated with L. infantum, while
in the other it was associated with L. tropica. The infants were treated as according to the recommendations of
the Ministry of Health. Both patients were cured in two months; defervescence, reduction of splenomegaly, and
healing of cutaneous lesions were all observed.
Conclusions: These singular patients illustrate the clinical polymorphism of CL and the necessity of updating the
differential diagnosis of leukemia-like syndromes, including VL, in children living in or travelling to known endemic
areas. These observations suggest a change in the Mediterranean VL phenotype that may be associated with CL.
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Background
Leishmaniases are vector-borne parasitic diseases caused
by the flagellated protozoa of the Leishmania genus. They
are prevalent in 98 countries and three territories on five
continents [1]. The spectrum of these diseases extends
from benign cutaneous lesions that heal spontaneously to
visceral forms [2]. Visceral leishmaniasis (VL) is a fatal
systemic disease, if left untreated. It is caused by the
Leishmania (L.) donovani complex in East Africa and
the Indian subcontinent and by L. infantum in Europe,
North Africa, and Latin America [3].
Zoonotic VL due to L. infantum is endemic in the
Mediterranean region [4]. If untreated within two years,
the disease usually leads to death, with approximately
300 000 new VL cases occurring each year globally [1].
In Morocco, the first case of VL was described in 1922
and in 2014, 86 VL cases were notified to the Ministry
of Health [5, 6]. The disease is endemic in the north of
the country, with a hundred cases reported per year,
mostly in children [6–8]. The disease is more threatening
in children than in adults due to the relative immaturity of
a child’s immune system, and is lethal if untreated [9].
In Morocco, cutaneous lesions due to Leishmania have
never been reported in a patient with zoonotic VL. In
contrast, 10–20% of patients develop cutaneous lesions
(Post Kala azar Dermal Leishmaniasis) as a sequel of
kala azar due to L. donovani [7, 10].
In this case study, we report on two retrospective
pediatric observations of unusual clinical presentations
with concurrent VL and cutaneous leishmaniasis (CL).
Case presentation
This retrospective analysis concerned two pediatric patients
diagnosed in 2012. Demographic data (age, sex, place of
residence, occupation for adults), diagnosis, and clinical
parameters were collected through a standardized in-
formation sheet.
Patient 1
A nine-month-old girl was admitted to the Children’s
Hospital (University Hospital Ibn Rochd of Casablanca)
with a seven-month history of febrile hepatosplenomegaly
(39 °C), anemia, pallor of mucous membranes, and pan-
cytopenia. She was living in Casablanca but her parents
reported a one-month stay in a northern endemic area of
VL the previous summer.
The parasitological diagnosis (microscopic examination
of bone marrow aspirate) showed the presence of Leish-
mania amastigotes. The screening for antibodies against
L. infantum (Leishmania IFA IgG, Vircell, Granada,
Spain) was also positive (title: 1/320; cut-off value: 1/40)
(see Table 1).
Furthermore, the clinical examination showed two
cutaneous lesions of 5 mm diameter: one evolutive ery-
thematous papule on the face and one scar lesion on the
arm. The aspect of these lesions and the history of travel in
a known endemic area of CL due to L. infantum or L.
tropica suggested CL lesions. To confirm this hypothesis,
dermic exudate was sampled from the active lesion. The
microscopic examination of the corresponding stained
smear was negative (absence of Leishmania amastigotes), as
was the culture on Novy – Mc Neal – Nicolle (NNN)
medium (absence of Leishmania promastigotes after one
month). The genotyping by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
(ITS1 – Hae 3) carried out directly on the dermal exudate
according to Schönian et al. (2003) and Mouttaki et al.
(2014) protocols showed L. infantum [11, 12] (see Table 1).
Meglumine antimoniate (Glucantime®) was administered
intramuscularly at the recommended dosage by the
Ministry of Health, i.e. 20 mg of pentavalent antimony
(Sb5+) per kg per day for 20 days [7]. The patient was
cured in two months; defervescence, reduction of the
spleen size, hematological restoration, negativation of
the parasitological control on bone marrow, and healing
of cutaneous lesions were all observed.
Patient 2
A one-year-old girl was admitted to the Children’s
Hospital (University Hospital Ibn Rochd of Casablanca)
with an impaired general condition and a three-month
history of febrile (39 °C) hepatosplenomegaly, anemia, and
pallor of mucous membranes. She was from an endemic
area of both VL due to L. infantum and CL due to L.
tropica (center of Morocco).
The bone marrow sample tested positive for Leishmania
amastigotes. Screening utilizing the indirect fluorescent anti-
body technique (IFAT) for antibodies against L. infantum
Table 1 Results of the biological examinations carried out on
patients 1 and 2
Biological examinations Patient 1 Patient 2
VL diagnosis
- Bone marrow stained smear + +
- Anti-L. infantum antibodies (IFAT)a + (1/320) + (1/80)
- Anti-L. infantum antibodies (WB) ND + (14–16 kD)
CL diagnosis
- Skin stained smear – +
- Culture (NNN) – +
- PCR-RFLP L. infantum L. tropica
+: Positive; −: Negative; ND: Not done
aCut-off value: 1/40
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(Leishmania IFA IgG, Vircell, Granada, Spain) was weakly
positive (title: 1/80; cut-off value: 1/40). This latter low value
and the altered general status led us to carry out a specific
western blot (WB) screening for anti-L. infantum antibodies
(LEISHMANIA Western Blot Ig G, LDBIO Diagnostics,
Lyon, France) and a screening for anti-HIV antibodies. Only
the L. infantum serology by WB was positive (antibodies
anti-14–16 kD proteins) (see Table 1).
Moreover, the clinical examination revealed two cutane-
ous papule lesions evolving for three months on the face,
which did not heal with a previously prescribed dermal
antibiotherapy before the patient’s hospital admission.
These lesions as well as the infant’s origin from a known
endemic area of CL due to L. infantum and/or L. tropica
led us to sample the dermal exudate. The corresponding
stained smear was positive as was the culture on NNN
medium. The genotyping by PCR-RFLP carried out on the
dermal sample and the isolate revealed L. tropica.
Meglumine antimoniate (Glucantime®) was administered
following the same protocol as for patient 1, but for 30 days.
The patient was cured after two months of treatment;
defervescence, reduction of splenomegaly, and healing of
cutaneous lesions were all observed.
Discussion and conclusions
In South Europe and North Africa, the Mediterranean
type of VL is usually caused by L. infantum, and infants
or children aged up to four years are frequently affected.
The incubation period ranges from 10 days to over one
year, and the disease onset is usually gradual. The common
symptoms are fever, malaise, shivering or chills, weight loss,
anorexia, and discomfort in the left hypochondrium. The
common clinical signs are non-tender splenomegaly, with
or without hepatomegaly, wasting and pallor of mucous
membranes. Signs of malnutrition (edema, skin and hair
changes) develop as the disease progresses. Intercurrent
infections are common [13].
Clinically, both infants observed in this study presented
clinical signs suggestive of VL. This hypothesis was rein-
forced by the fact that they either lived or stayed in known
endemic VL foci according to Ministry of Health data.
The positive bone marrow smear and the anti-L. infantum
serology allowed us to confirm VL in both cases. These
children were then treated with Glucantime® and were
cured within two months. In Morocco, the recommended
treatment for VL is antimonials (20 mg Sb+/kg/day for
three weeks), and the cure rate is 99% [7, 14].
Furthermore, both infants presented signs suggestive
of CL, as follows: cutaneous lesions on exposed skin
surfaces (face and arm), history of resistance to dermal
antibiotic treatment, and history of living or traveling
the previous summer to known endemic foci of CL due
to L. tropica or L. infantum. While the conventional para-
sitological diagnostic methods (dermal smears and culture)
confirmed the diagnosis only for patient 2, the genotyping
on the dermal samples revealed L. infantum in patient 1
and L. tropica in patient 2.
In Morocco, VL is a zoonotic rural disease endemic in
northern regions and cases are sporadically reported in
some southern regions. Leishmania infantum is also
responsible for sporadic CL in North Africa in the same
geographical area as VL [15]. In Morocco, the first L.
infantum CL patient was reported in 1996 from an active
focus of canine VL in the northern Rif mountains [16]. In
fact, most CL cases due to L. infantum are notified from
one focus (Sidi Kacem in the northwest), where sporadic
cutaneous forms have been described as two-year-course
single lesions [17–19]. To our knowledge, the association
of VL and CL in the same human immunocompetent host
has not been previously described.
Leishmania tropica is responsible for anthroponotic
CL in Morocco. In the 1980s, the disease was hypoendemic
in center-south rural foci. In the 1990s, urban epidemic foci
appeared in the north [20, 21]. In fact, CL due to L. tropica
has the widest geographic distribution in the country and
the highest incidence in North Africa [8, 15, 22].
The CL cases presented in this study are interesting
due to their association with a visceral syndrome. Until
now, the clinical definition of VL in Morocco by the
Ministry of Health highlighted the absence of cutaneous
lesions. Thus, L. infantum could be responsible for both
the visceral and cutaneous symptomatology in patient 1,
whereas two different species, L. infantum and L. tropica,
could be respectively responsible for the visceral and cuta-
neous symptomatology in patient 2.
For patient 1 (CL due to L. infantum), the symptomatol-
ogy could be explained either by the inoculation of differ-
ent viscerotropic and dermotropic strains of L. infantum
through the vector bite, or by the immunological status of
children, which would have allowed the visceral dissemin-
ation of a dermotropic strain of L. infantum. Patient 2,
who had CL due to L. tropica, lived in a co-endemic re-
gion of VL due to L. infantum and CL due to L. tropica.
We could not discriminate between L. tropica and L.
infantum on the bone marrow. We therefore cannot state
with certainty that this patient’s VL was due to L. infan-
tum. Few cases of VL caused by L. tropica have been re-
ported in India, Iran, and Israel [10, 13, 23].
Furthermore, IFAT serology showed a low antibody
title (1/80) close to the cut-off value in patient 2, which
is consistent with a cross-reaction. Cross-reactions have
also been described with L. tropica using WB [24]. If the
VL of this patient was caused by L. infantum, this would
highlight the possibility of a coinfection by two endemic
species in the same focus. It is usually considered that
vector and human hosts are infected by a single species
and that the natural infection by one Leishmania species
would protect against reinfections by homologous or
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heterologous species [25, 26]. However, natural human
coinfections have been reported in Bolivia, Brazil, Iran,
Iraq, Mexico, and Peru [25, 27]. In Morocco, these ob-
servations must be kept in mind due to the increasing
number of reported co-endemic CL foci due to L. infan-
tum and L. tropica, or L. tropica and L. major [8, 17].
Finally, these patients illustrate the clinical polymorphism
of CL and its difficult clinical diagnosis, even in endemic
regions. They also highlight the importance of updating the
differential diagnosis of leukemia-like syndromes, including
VL in infants living in or travelling to known endemic
areas. Indeed the patients staying during the summer in
known foci was a pivotal anamnestic fact that directed the
clinical diagnosis towards VL and then CL that were con-
firmed by the biological examinations. Our observations
also suggest a change in the Mediterranean VL phenotype
that may be associated to cutaneous lesions. It is thus
important to characterize Leishmania species in any un-
usual clinical situation and to report particular cases such
as coinfections in order to contribute to better epidemio-
logical and physiopathological knowledge of leishmaniases
in endemic areas.
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